Blockchain Registration Transaction Record

Helus Pharma Strengthens Leadership with Key Hires and Scientific Advisor

Helus Pharma appoints Regina Donohue as CPO and Suresh Durgam to SAB, bolstering leadership as it advances novel serotonergic agonists for depression and anxiety.

This news matters because Helus Pharma is advancing promising treatments for major depressive disorder and generalized anxiety disorder, conditions affecting millions worldwide. The addition of seasoned executives from Intra-Cellular, a company with a successful track record in CNS drug commercialization, signals that Helus is preparing for potential market entry. If HLP003 and HLP004 succeed in clinical trials, they could offer new hope for patients who have not responded to existing therapies, potentially reshaping the mental health treatment landscape. Investors and healthcare stakeholders should monitor these developments closely.